PROTOCOL OUTLINE: This is a multicenter study. Patients receive oral prednisone on days
0-10. Beginning on day 1, patients undergoing autologous peripheral blood stem cell (PBSC)
transplantation receive filgrastim (G-CSF) subcutaneously daily until leukapheresis is
completed. Leukapheresis begins on approximately day 4 and continues until adequate CD34+
PBSC are collected.
PBSC are collected from syngeneic donors in a similar manner. Patients undergo total-body
irradiation twice daily on days -5 and -4. Patients receive cyclophosphamide IV on days -3
and -2 and anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5. Patients undergo
autologous or syngeneic PBSC transplantation on day 0. Following PBSC transplantation,
patients receive oral prednisone on days 7-30 and G-CSF IV daily beginning on day 0 and
continuing until blood counts recover.
Patients are followed at 30, 80, and 90 days, monthly for 6 months, and then at 1 and 2
years.
Interventional
Primary Purpose: Treatment
Richard Nash
Study Chair
Fred Hutchinson Cancer Research Center
Unspecified
199/15796
NCT00014755
December 1997
Name | Location |
---|---|
Fred Hutchinson Cancer Research Center | Seattle, Washington 98109 |
University of Colorado Cancer Center | Denver, Colorado 80262 |
University of Nebraska Medical Center | Omaha, Nebraska 68198-3330 |
Washington University Barnard Cancer Center | Saint Louis, Missouri 63110 |
City of Hope National Medical Center | Los Angeles, California 91010 |
Duke University Medical Center | Durham, North Carolina 27710 |